evoke semaglutide fails to slow cognitive decline in early Alzheimer's A Critical Appraisal of the

Semaglutide and other GLP-1 receptor agonists have transformed weight loss outcomes, with clinical trials showing average weight reductions of 15-22% over 68 weeks

The Medicines and Healthcare products Regulatory Agency (MHRA) has updated the product information to include the small risk of severe acute pancreatitis in patients taking GLP-1s, prescribed for treating type 2 diabetes and weight management

Telitacicept, a transmembrane activator and cyclophilin ligand interactor (TACI)-Fc fusion protein, has shown significant clinical effects in the treatment of immunoglobulin A nephropathy (IgAN) as demonstrated in a phase II randomized placebo-controlled trial

Adding 2 mL of bacteriostatic water to a 5 mg vial yields a concentration of 2,500 mcg/mL